Merck’s HIV drug doravirine looks solid — though far less stellar than rivals — in 1st PhIII
Merck’s late-stage antiviral doravirine (MK-1439) came through in its first Phase III study, matching up nicely against J&J’s blockbuster Prezista.
The non-nucleoside reverse transcriptase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
